On 5 May 2023, France reported an increase in cases of severe neonatal sepsis associated with Enterovirus (Echovirus-11 (E-11)). A total of nine cases of neonatal sepsis with hepatic impairment and multi-organ failure were reported between July 2022 and April 2023 from four hospitals in three regions of France. As of 5 May 2023, seven cases have died and two were still hospitalized in neonatal unit.
The current increase in incidence and severity in neonates, associated with a recombinant lineage of E-11 that previously was not detected in France, and is considered unusual due to the extremely rapid deterioration and associated case fatality rate amongst the affected babies.
Based on the limited information available, WHO assesses the public health risk for the general population to be low, despite the concerning nature of the increase.
Description of the cases
On 5 May 2023, France reported nine cases of severe neonatal sepsis associated with hepatic impairment and multi-organ failure including seven associated deaths. Of these nine cases, eight were preterm (born before 38 weeks of gestation). Four pairs of twins were affected and presented with late-onset neonatal sepsis (occurring after one week of birth to three months).
The cases were reported from four hospitals in three regions between July 2022 and April 2023. Of the nine reported cases, six were reported in 2022 (two cases each in July, October, and December) and three were reported in 2023 (one case in January and two cases in April).
All cases presented with one or more clinical signs less than seven days after birth, suggesting a mother-to-child transmission route. The clinical presentation of these cases was considered to be atypical due to their extremely rapid deterioration and the associated case fatality rate. As of 5 May 2023, seven cases have died and two were still hospitalized in the neonatal unit; their short-term prognosis is no longer threatened.
Enterovirus reverse transcription polymerase chain reaction (RT-PCR) testing of all nine cases (including blood samples, throat swabs, nasopharyngeal swabs, cerebrospinal fluid samples, and/or post-mortem biopsies) confirmed the presence of enterovirus, typed as Echovirus-11 (E-11). E-11 maternal infection was confirmed by RT-PCR and enterovirus genotyping by analyzing blood samples from four out of five mothers. All tested mothers presented with gastrointestinal signs or fever within the three days before or at delivery.
Sequence analyses of all typed enterovirus infections in 2022 showed the circulation of at least two lineages of recombinant origin, of which the predominant one included all the sequences associated with the nine cases together with sequences associated with non-neonatal or non-severe neonatal infections. Further genetic analyses are ongoing.
According to historical data from 2016 to 2021, E-11 represented 6.2% (3 of 48) of reported severe neonatal infections with known enterovirus type while this proportion increased to 55% (11 of 20) in 2022.
Epidemiology of disease
Enteroviruses are a group of viruses that can cause various infectious illnesses and are responsible for annual epidemics. Illness is usually mild but has been found to affect neonates differently and sometimes more severely than older children and adults. There are multiple transmission routes, particularly in the neonatal period, including intrapartum by exposure to maternal blood, secretions, and/or stool, or postnatally from close contacts with infected caregivers. Echovirus 11 (E-11) is a positive-strand RNA virus belonging to the genus Enterovirus of the family Picornaviridae.
The infections can cause severe inflammatory illnesses in neonates, including severe acute hepatitis with coagulopathy.
Public health response
On 28 April 2023, the French national reference centre for enteroviruses and parechoviruses informed clinicians and virologists involved in the care of newborns, to reinforce the diagnosis and surveillance of enterovirus infection in neonates with severe sepsis through a professional network. In particular, the message focused on:
What to do in newborns with a picture of severe sepsis of indeterminate aetiology to sensitize about the risk of transmission.
Clinicians were invited to systematically consider enterovirus infection in neonates with severe liver failure, enterocolitis, meningoencephalitis, or myocarditis.
Close monitoring of liver function, cardiac function, neurological function, and risk of enterocolitis were recommended in neonates with severe neonatal sepsis of undetermined aetiology.
Clinicians were also invited to undertake an early notification of referral hospitals in order to discuss potential therapeutic options.
The risk of maternal transmission of E-11 was raised and recommendations made to monitor the infant closely for at least 7 days if the mother was known to have had an infection before or during childbirth.
The importance of collecting additional samples (blood, stool, and nasopharyngeal) in newborns and mothers for enterovirus.
The importance of genotyping EV-positive samples: Clinical virologists were invited to send EV-positive samples in a prospective manner, especially from patients presenting with severe clinical signs. Samples are sent to the National Reference Laboratories for genotyping and genome studies.
Continuous information sharing regarding this event among France and other Member States (through the European Non-Polio Enterovirus Network (ENPEN)), the European Centre for Disease Prevention and Control (ECDC) and WHO is ongoing. To date, no comparable increase of E-11 cases associated with neonatal sepsis has been observed in countries that have reported to the ECDC (Belgium, Denmark, Netherlands, Norway, and Spain) in 2022 and 2023.
WHO risk assessment
A review of the epidemiological data collected from 2016 to 2022 in France through routine surveillance of enterovirus infections among hospitalized patients showed a significant increase in incidence and mortality for all severe neonatal infections associated with E-11, defined as infections with at least one organ failure and/or requiring admission to intensive care.
A total of 443 enterovirus neonatal infections (severe and non-severe types) including seven deaths (case fatality rate, (CFR) 1.6%) were reported in France in 2022. Of these, 72% (n=317) had a known enterovirus type. E-11 was the predominant circulating enterovirus type (all ages included) and was identified in 30.3% (96 of 317) of neonatal infections (severe and non-severe) with known enterovirus type. It has been continuously detected since June 2022.
Of the reported neonatal infections in 2022, 4.5% (22 of 443) were classified as severe. Of these 20 had known enterovirus types. E-11 represented 55% (11 of 20) of these cases as compared to 6.2% (3 of 48) of cases with known enterovirus type out of the total reported severe neonatal infections (n=62) between 2016 to 2021.
In 2022, there were seven deaths (case fatality rate, (CFR) 1.6%) out of the cumulative 443 enterovirus neonatal infections recorded in 2022 (six associated with E-11), compared to seven deaths (CFR 0.4%), out of 1774 neonatal infections from 2016 to 2021(none associated with E-11). As mentioned above, there have also been seven deaths so far in 2023.
Sequence analyses showed the circulation of at least two lineages of recombinant origin, of which the predominant one included all the sequences associated with the nine severe cases together with sequences associated with non-neonatal or non-severe neonatal infections. This new variant of E-11 had not been observed in France before July 2022, nor elsewhere based on available sequences on Genbank, as of 28 April 2023. As of 5 May 2023, E-11 sequences retrieved from samples collected in 2023 all belong to this predominant lineage. Although higher pathogenicity of this new lineage cannot be excluded, the severity of infections may also be explained by the young age, prematurity, and the absence of maternal immunity. Further analyses are warranted to delineate the characteristics of this recombinant virus.
Based on the limited information available, WHO assesses the public health risk for the general population to be low. However, asymptomatic carriage and shedding of infectious viruses are a feature of enterovirus infection. Echovirus infection was confirmed in four out of five mothers by analyzing blood samples three days before or at delivery. There have been previous reports of severe E-11 infection in twin neonates, however, the observation of four sets of twins amongst nine cases is more than expected. As non-polio enterovirus infection is often not a notifiable disease in Member States, additional cases of severe neonatal enterovirus infection may have gone undiagnosed and/or unreported.
WHO advice
Non-polio enteroviruses are common and distributed worldwide. Although infections often are asymptomatic, some may present with respiratory tract infections. Symptoms include fever, runny nose, and body weakness. These viruses are also associated with occasional outbreaks in which an unusually high proportion of patients develop clinical disease, sometimes with serious and fatal consequences. Clinicians managing neonates and young infants presenting with circulatory shock should consider an underlying diagnosis of sepsis and perform appropriate diagnostic investigations, including testing for enteroviruses.
Health and care workers working with samples suspicious of non-polio enteroviruses should be properly trained to collect, store, and transport various samples. If samples are referred domestically and/or internationally for confirmation, typing, or sequencing purposes, appropriate national and international regulations on the transport of infectious substances should be strictly followed. Laboratories that perform sequencing should consider sharing genetic sequence data through publicly accessible databases.
No specific antiviral therapy for echovirus infection is available, and treatment focuses on preventing complications. Health facilities caring for neonate populations in France should familiarize themselves with the signs and symptoms of enterovirus and maintain vigilance for potential healthcare-associated infection cases and outbreaks in wards providing neonatal care.
Healthcare facilities and health and care workers in units working with neonates should implement infection prevention and control measures with a focus on adherence to WHO “Your 5 Moments for Hand Hygiene,” visitor restriction, re-enforcing the importance of cleaning and disinfection of the environment and use of contact precautions when caring for neonates suspected or confirmed to have E-11. For confirmed neonates consider isolation, ensure pacifiers and baby bottles are not shared and educate mothers on personal hygiene and handwashing during change of diapers. WHO provides training for health and care workers on preventing maternal and neonatal sepsis which can be accessed on Open WHO.
About WHO
The World Health Organization provides global leadership in public health within the United Nations system. Founded in 1948, WHO works with 194 Member States, across six regions and from more than 150 offices, to promote health, keep the world safe and serve the vulnerable. Our goal for 2019-2023 is to ensure that a billion more people have universal health coverage, to protect a billion more people from health emergencies, and provide a further billion people with better health and wellbeing.